The Hourly View for MRK
Last Updated February 16, 2021, 12:41 GMT
At the time of this writing, MRK’s price is up $0.18 (0.24%) from the hour prior. This move is a reversal from the hour prior, which saw price move down. Regarding the trend, note that the strongest trend exists on the 100 hour timeframe. The moving averages on the hourly timeframe suggest a choppiness in price, as the are all in a mixed alignment — meaning the trend across timeframes is inconsistent, indicating a potential opportunity for rangebound traders.
Merck & Co Inc Daily Price Recap
The back and forth price flow continues for Merck & Co Inc, which started today off at 75 US dollars, up 0.35% ($0.26) from the day prior. This move happened on lower volume, as yesterday’s volume was down 23.35% from the day before — and down 32.72% from the same day the week before. Let’s take a look at the daily price chart of Merck & Co Inc.
Merck & Co Inc Technical Analysis
Volatility for Merck & Co Inc has been contracting over the past two weeks relative to volatility over the past month. Whether volatility reverts will be something to watch. Trend traders will want to observe that the strongest trend appears on the 30 day horizon; over that time period, price has been moving down. Also of note is that on a 90 day basis price appears to be forming a base — which could the stage for it being a support/resistance level going forward. Or to view things another way, note that out of the past 10 days Merck & Co Inc’s price has gone down 6 them.
Overheard Around the Web
Here’s what one trader on StockTwits recently had to say in regards to MRK:
$APTO : Interesting company – very slow stock lately / Updates from key studies in 2021 (no timeline) / Well funded to 2023 💰 / Recent 13Gs from this month👇🏽
➖Nantahala Capital Management (7,272,673 shares / 8.20% ownership (Increased ownership by 20.13%)
➖Orbimed Capital (8,030,000 shares / 9.04% ownership)
➖DRW Investments (7,976,176 shares / 8.98% ownership)
Nantahala Capital Management held the most valuable stake in ArQule, Inc. which was worth $72.1 million at the end of the Q3 2019 before $MRK paid $2.7B or 104% premium in a buyout deal in Dec 2019.
➖The Buyout was centered on ARQ 531 – BTK inhibitor that triggered durable responses in patients with B-cell malignancies in an early-phase trial. Aptose's lead pipeline candidate uses a similar mechanism of action as ArQule's lead candidate.
➖Big pharma has a history of paying considerable sums of money for successful BTK inhibitors
Wish there was timeline of catalysts here 🤨